Open Journal Systems

Cover Image

A literature review of pandemic novel coronavirus disease 2019 and potential drugs treatment

Venkatesh Balaji Hange, Shishir Mohan Devki


Background: Coronaviruses (CoVs) belong to a family that comes under the order “Nidovirales.” Nidovirales order includes the viruses that use a nested set of mRNAs for their replication. CoV disease 2019 (COVID)-19 is a βCoV-2, CoV of the same subgenus as severe acute respiratory syndrome (SARS) virus, but in a different clad. The constitution of the receptor-binding gene region is very like to that of the SARS-CoV, and the virus has been demonstrated to utilize the same receptor, the angiotensin-converting enzyme 2, for entrance into respiratory cells. There are presently no drugs or vaccinations that are known to be successful for SARS-CoV-2 management or preventing the spread as per various major health officials. Aim: This review describes various drug treatment options available against COVID-19. It focuses on the use virology of SARS-COV2, potential drugs that can be utilized to treat COVID-19 infection, their dosages, advantages, side effects, and indications. Conclusion: As there are no definitive treatment modes accessible to cure SARS-COV2 infection to this date, drug repurposing can provide effective tool to combat against COVID-19 until definitive drugs or vaccines discovered to treat SARS-CoV2 infection. Various antiviral, antiparasitic, and antimalarial drugs, antibodies, Vitamin C, Vitamin D, melatonin hormone, etc., are effective to reduce viral load of COVID-19. Clinical Significance: Drug repurposing and previous or recent clinical experiences with CoV infection provide an efficient weapon to COVID-19 infection. They are effective in not only reducing viral load of COVID-19 infection but also minimize the symptoms related to SARS.


Coronavirus disease 2019; Coronaviruses; Outbreak; Respiratory illness; Transmission; Infection control and management

Full Text:

Abstract PDF


Fehr AR, Perlman S. Coronaviruses: An overview of their replication and pathogenesis. Coronaviruses 2015;1282:1-23.

Gallagher TM, Buchmeier MJ. Coronavirus spike proteins in viral entry and pathogenesis. Virology 2001;279:371-4.

Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814-20.

Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol 2020;92:401-2.

Novel Coronavirus (2019-nCoV) Situation Report 48. Available from: coronaviruse/situation-reports/20200308-sitrep-48-covid-19. pdf?sfvrsn=16f7ccef_4. [Last accessed on 2020 Mar 13].

Rismanbaf A. Potential treatments for COVID-19; a narrative literature review. Arch Acad Emerg Med 2020;8:e29.

Smith T, Bushek J, Prosser T. COVID-19 Drug Therapy Potential Options. Netherlands: Elsevier; 2020.

Rabaan AA, Al-Ahmed SH, Haque S, Sah R, Tiwari R, Malik YS, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV: A comparative overview. Infez Med 2020;28:174-84.

Özdemir Ö. Coronavirus disease 2019 (COVID-19): Diagnosis and management. Erciyes Med J 2020;42:242-7.

Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016;3:237-61.

Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020;52:56-65.

Zeng Q, Langereis MA, Van Vliet AL, Huizinga EG, De Groot RJ. Structure of coronavirus hemagglutinin-esterase offers insight into corona and influenza virus evolution. Proc Natl Acad Sci U S A 2008;105:906-59.

Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R, Yatoo MI, Patel SK, et al. SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic virus-a review. Front Immunol 2020;28:174–184.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.

Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, et al. Passive immunotherapy: Assessment of convalescent serum against Ebola virus Makona infection in nonhuman primates. J Infect Dis 2016;214:S367-74.

Shneider A, Kudriavtsev A, Vakhrusheva A. Can melatonin reduce the severity of COVID-19 pandemic? Int Rev Immunol 2020;39:153-62.

Zhang R, Wang X, Ni L, Di X, Ma B, Niu S, et al. COVID-19: Melatonin as a potential adjuvant treatment. Life Sci 2020;250:117583.

Mistraletti G, Sabbatini G, Taverna M, Figini MA, Umbrello M, Magni P, et al. Pharmacokinetics of orally administered melatonin in critically ill patients. J Pineal Res 2010;48:142-7.

Chang R, Sun WZ, Ng TB. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents 2020;56:106118.

Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020;92:418-23.

Ishikado A, Imanaka H, Takeuchi T, Harada E, Makino T. Liposomalization of lactoferrin enhanced it’s anti-inflammatory effects via oral administration. Biol Pharm Bull 2005;28:1717-21.

Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol 2020;92:479-90.

Genentech. Actemra (Tocilizumab) Injection Package Insert. South San Francisco, CA: Genentech Inc.; 2019.

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117:10970-5.

Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit Cathepsin L in the late endosome/ lysosome and block the entry of Ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 2016;291:9218-32.

Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: An alternative drug for the treatment of COVID-19? Int J Antimicrob Agents 2020;55:105944.

Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin Potently Blocks the Cell Entry of 2019-nCoV. New York: bioRxiv; 2020.

Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 2020;6:315-31.

McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: A review of early and emerging options. Open Forum Infect Dis 2020;7:ofaa105.

Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020;323:1488-94.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020;383:1787-99.

Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data. BMJ 2017;356:i6583.

Kakodkar P, Kaka N, Baig MN. A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19). Cureus 2020;12:e7560.

Carr AC. A new clinical trial to test high-dose Vitamin C in patients with COVID-19. Crit Care 2020;24:133.

Fowler AA 3rd, Truwit JD, Hite RD, Morris PE, DeWilde C, Priday A, et al. Effect of Vitamin C infusion on organ failure and biomarkers of inflammation and vascular injury in patients with sepsis and severe acute respiratory failure: The CITRIS-ALI randomized clinical trial. JAMA 2019;322:1261-70.

Paprocki M. Nonsteroidal anti-inflammatory drugs (NSAIDs) in COVID-19 patient. Disaster Emerg Med J 2020;5:108-9.

González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J 2008;10:42-6.

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDAAPPROVED drug ivermectin inhibits the replication of sarscov- 2 in vitro. Antiviral Res 2020;178:104787.

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020;14:58-60.

Agrawal S, Goel AD, Gupta N. Emerging prophylaxis strategies against COVID-19. Monaldi Arch Chest Dis 2020;90:1289.

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;56:105949.

Wang BX, Fish EN. Global virus outbreaks: Interferons as 1st responders. Semin Immunol 2019;43:101300.


  • There are currently no refbacks.